vimarsana.com

Optimal Biomarker Using Quantitative Muscle News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Edgewise Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

– Announced positive 12-month topline results from the ARCH open label study of EDG-5506 in adults with Becker muscular dystrophy – – Advancing Phase 2 trial of EDG-5506 in Becker muscular. -Today at 08:03 am- MarketScreener

Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

– Sustained positive trend in North Star Ambulatory Assessment (NSAA) scores relative to BMD natural history – – Significant decreases in levels of serum creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), enzyme biomarkers associated with skeletal muscle damage– – EDG-5506 was well-tolerated at all doses – – Company continuing to enroll patients with BMD in the CANYON Phase 2 trial which now includes a pivotal cohort called GRAND CANYON – – Edgewise leadership to discuss ARCH findings on Tuesday, June 27 at 8:30 a.m. Eastern Time at virtual investor event –

Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.